11.30am – 1pm GMT, 26 November 2025 ‐ 1 hour 30 mins
Panel
Senior Policy and Public Affairs Manager, BioIndustry Association
What does your role at BIA involve?
Rosie leads the BIA’s policy work on access to medicines, rare diseases, cell and gene therapies and antimicrobial resistance. This involves providing the secretariat for the BIA’s Cell and Gene Therapy Advisory Committee (CGTAC) and Rare Disease Industry Group (RDIG). She is also responsible for organising the BIA’s annual Parliament Day, which brings CEOs and senior representatives from BIA member companies to Westminster to meet with politicians and policymakers.
Previous experience
Previously, Rosie worked as a Senior Research Consultant at a Westminster-based public affairs agency, where she supported clients from a range of sectors, including pharmaceuticals, technology and financial services. Prior to that, Rosie worked as a Management Consultant at KPMG, where she assisted on financial and regulatory projects with large corporate clients. She has a BA in Human, Social and Political Sciences from the University of Cambridge.
Chief Executive Officer, eXmoor Pharma
Lucy joined eXmoor after eight years at the Centre for Process Innovation (CPI) with her final position as Director of Biologics and COVID response. She recently led the establishment of the UK’s RNA Centre of excellence in response to the COVID-19 pandemic as a member of the UK Vaccines Taskforce. In 2013, as the Lead Biopharmaceutical Engineer at CPI, Lucy collaborated with eXmoor on the concept design of the organisation’s Darlington-based National Biologics Manufacturing Centre. Previously, she was an academic at Newcastle University in both the Business School and Chemical Engineering Departments where she worked with Professors Lyddiatt and Whitaker to understand the route to widespread adoption and process industrialisation of advanced therapies. Lucy ins a founding member and director of the ATMP Manufacturing Community.